No abstract available.
Plasminogen Activators* ; Plasminogen*

No abstract available.
Plasminogen Activators* ; Plasminogen* ; Pulmonary Embolism*

No abstract available.
Urokinase-Type Plasminogen Activator*

No abstract available.
Chickens* ; Plasminogen* ; Tendons*

The utility of intravenous tissue plasminogen activator (IV t-PA) in improving the clinical outcomes after acute ischemic stroke has been well demonstrated in past clinical trials. Though multiple initial small series of endovascular stroke therapy had shown good outcomes as compared to IV t-PA, a similar beneficial effect had not been translated in multiple randomized clinical trials of endovascular stroke therapy. Over the same time, there have been parallel advances in imaging technology and better understanding and utility of the imaging in therapy of acute stroke. In this review, we will discuss the evolution of endovascular stroke therapy followed by a discussion of the key factors that have to be considered during endovascular stroke therapy and directions for future endovascular stroke trials.
Stroke* ; Tissue Plasminogen Activator

We report removing a large subretinal hemorrhage by means of vitrectomy combined with the use of tissue plasminogen activator(tPA) to facilitate clot removal. A 25-year-old man had a 4 days history of visual loss in the right eye after blunt trauma. The right fundus had a large subretinal hemorrhage involving macula. Surgery was performed the following day. A small retinotomy was made, through which tPA was injected into the subretinal space and through which the dissolved clot was removed. The use of tPA minimizes surgical manipulation of the retina and greatly reduces the size of the retinotomy reguired for evacuation of subretinal bood. Although the long-term prognosis is guarded, this case does suggest that tPA may be a useful adjunct in managing of subretinal hemorrhage.
Adult ; Hemorrhage* ; Humans ; Plasminogen ; Prognosis ; Retina ; Tissue Plasminogen Activator* ; Vitrectomy

No abstract available.
Humans ; Intracranial Hemorrhages* ; Plasminogen Activators* ; Plasminogen* ; Rivaroxaban* ; Thrombolytic Therapy

Thromboembolism is a crucial part of the global disease burden. It has high incidence, high mortality and disability rates, and the mechanism of occurrence and development is extremely complex. It is difficult to detect the disease in the early stage so that we have trouble with clinical prevention and treatment in general. At present, four items of blood coagulation and D-dimer have been widely used in the evaluation and auxiliary diagnosis of thromboembolism, the monitoring of effect for antithrombotic drugs and other fields. The thrombus biomarkers including thrombin-antithrombin complex (TAT), thrombomodulin (TM), tissue plasminogen activator-inhibitor complex (t-PAIC) and α2-plasmin inhibitor-plasmin complex (PIC) fill the gap of laboratory diagnosis before clinical symptoms appear in some degree. This article aims to explain the current application status of TAT, TM, t-PAIC and PIC in thromboembolism and explore their potential application value, so as to provide a reference for selecting appropriate early monitoring indicators for high-risk population of thromboembolism.
Humans ; Tissue Plasminogen Activator ; Plasminogen Inactivators ; Thrombomodulin ; Thromboembolism ; Biomarkers

Thromboembolism is a crucial part of the global disease burden. It has high incidence, high mortality and disability rates, and the mechanism of occurrence and development is extremely complex. It is difficult to detect the disease in the early stage so that we have trouble with clinical prevention and treatment in general. At present, four items of blood coagulation and D-dimer have been widely used in the evaluation and auxiliary diagnosis of thromboembolism, the monitoring of effect for antithrombotic drugs and other fields. The thrombus biomarkers including thrombin-antithrombin complex (TAT), thrombomodulin (TM), tissue plasminogen activator-inhibitor complex (t-PAIC) and α2-plasmin inhibitor-plasmin complex (PIC) fill the gap of laboratory diagnosis before clinical symptoms appear in some degree. This article aims to explain the current application status of TAT, TM, t-PAIC and PIC in thromboembolism and explore their potential application value, so as to provide a reference for selecting appropriate early monitoring indicators for high-risk population of thromboembolism.
Humans ; Tissue Plasminogen Activator ; Plasminogen Inactivators ; Thrombomodulin ; Thromboembolism ; Biomarkers

Urokinase use after stereotaxic evacuation of hematoma became a popular method in treatment of hypertensive intracerebral hematoma. We obtained excellent result in evacuaIon of the hematoma which was remained after stereotaxic evacuation or direct approach for 24 raumatic intracerebral hematoma cases. And we found several advantages in this method compared with standard treatment modalities. We think that this is a new, effective treatment method for traumatic intracerebral hematoma.
Hematoma* ; Urokinase-Type Plasminogen Activator*